Enliven Therapeutics: Compelling Early ELVN-001 Data and De-Risked Development Path Support Buy Rating

TD Cowen analyst Phil Nadeau has maintained their bullish stance on ELVN stock, giving a Buy rating on March 3.

Phil Nadeau has given his Buy rating due to a combination of factors tied to Enliven Therapeutics’ lead asset and development trajectory. He views ELVN-001’s Phase I data in chronic myeloid leukemia as showing a strong, competitive efficacy profile, with meaningful rates of major molecular responses and deep molecular responses in heavily pretreated patients.

Phil also emphasizes management’s view that the more mature 80 mg cohort likely offers the truest read on the drug’s potential, reducing the risk that early, biased response data inflate expectations. With updated Phase Ia/b results expected around mid-year, plans to begin a Phase III study in the second half, and ELVN highlighted as a top small‑ and mid‑cap idea at the firm, he sees a favorable risk‑reward and supports a Buy recommendation.

Nadeau covers the Healthcare sector, focusing on stocks such as Kura Oncology, Syndax Pharmaceuticals, and Rhythm Pharmaceuticals. According to TipRanks, Nadeau has an average return of 8.5% and a 48.24% success rate on recommended stocks.

In another report released on March 3, LifeSci Capital also maintained a Buy rating on the stock with a $39.00 price target.